600998.SS
Jointown Pharmaceutical Group Co., Ltd [600998.SS] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
600998.SS Stock Summary
In the News
600998.SS Financial details
Company Rating
Buy
Market Cap
31.47B
Income
2.17B
Revenue
151.84B
Book val./share
6.33
Cash/share
3.86
Dividend
0.5
Dividend %
6.92%
Employees
30.14K
Optionable
No
Shortable
Yes
Earnings
27 Apr 2024
P/E
6.44
Forward P/E
-
PEG
-5.68
P/S
0.19
P/B
0.59
P/C
2.19
P/FCF
7.66
Quick Ratio
0.99
Current Ratio
1.24
Debt / Equity
0.69
LT Debt / Equity
0.1
-
-
EPS (TTM)
0.56
EPS next Y
-
EPS next Q
-
EPS this Y
-15.87%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
1.58%
Revenue last 5Y
10.01%
Revenue Q/Q
-6.06%
EPS Q/Q
-35%
-
-
-
-
SMA20
-
SMA50
14.29%
SMA100
14.29%
Inst Own
-
Inst Trans
-
ROA
2%
ROE
9%
ROC
0.09%
Gross Margin
8%
Oper. Margin
2%
Profit Margin
1%
Payout
76%
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
6.5-8.95
52W High
+5.75%
52W Low
+41%
RSI
66
Rel Volume
1.31
Avg Volume
17.21M
Volume
22.46M
Perf Week
5.75%
Perf Month
7.36%
Perf Quarter
12.8%
Perf Half Y
10.73%
-
-
-
-
Beta
0.133
-
-
Volatility
0.21%, 0.18%
Prev Close
-0.7%
Price
8.46
Change
1.68%
600998.SS Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
| Metric | History | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 31.85 | 25.4 | 28.36 | 31.32 | 35.92 | |
| Net income per share | 0.49 | 0.44 | 0.79 | 0.63 | 0.53 | |
| Operating cash flow per share | 0.45 | 0.71 | 0.88 | 0.88 | 1.02 | |
| Free cash flow per share | -0.22 | 0.4 | 0.51 | 0.53 | 0.7 | |
| Cash per share | 4.64 | 3.01 | 3.79 | 4.68 | 4.48 | |
| Book value per share | 6.75 | 4.79 | 5.58 | 5.99 | 6.3 | |
| Tangible book value per share | 6.93 | 4.95 | 5.83 | 6.2 | 6.62 | |
| Share holders equity per share | 6.75 | 4.79 | 5.58 | 5.99 | 6.3 | |
| Interest debt per share | 4.67 | 4.03 | 4.79 | 4.64 | 4.2 | |
| Market cap | 18.96B | 26.56B | 34.05B | 27.6B | 24.43B | |
| Enterprise value | 18.15B | 28.94B | 36.93B | 29.88B | 22.46B | |
| P/E ratio | 14.14 | 15.38 | 11.07 | 11.27 | 11.72 | |
| Price to sales ratio | 0.22 | 0.27 | 0.31 | 0.23 | 0.17 | |
| POCF ratio | 15.52 | 9.59 | 9.89 | 7.98 | 6.13 | |
| PFCF ratio | -31.99 | 16.85 | 17.14 | 13.31 | 8.91 | |
| P/B Ratio | 1.03 | 1.42 | 1.56 | 1.18 | 0.99 | |
| PTB ratio | 1.03 | 1.42 | 1.56 | 1.18 | 0.99 | |
| EV to sales | 0.21 | 0.29 | 0.33 | 0.24 | 0.16 | |
| Enterprise value over EBITDA | 5.7 | 7.02 | 7.78 | 7.27 | 4.41 | |
| EV to operating cash flow | 14.85 | 10.45 | 10.72 | 8.64 | 5.63 | |
| EV to free cash flow | -30.61 | 18.36 | 18.59 | 14.41 | 8.19 | |
| Earnings yield | 0.07 | 0.07 | 0.09 | 0.09 | 0.09 | |
| Free cash flow yield | -0.03 | 0.06 | 0.06 | 0.08 | 0.11 | |
| Debt to equity | 0.64 | 0.78 | 0.81 | 0.73 | 0.62 | |
| Debt to assets | 0.18 | 0.2 | 0.22 | 0.2 | 0.16 | |
| Net debt to EBITDA | -0.26 | 0.58 | 0.61 | 0.56 | -0.39 | |
| Current ratio | 1.29 | 1.28 | 1.29 | 1.28 | 1.27 | |
| Interest coverage | 2.06 | 2.92 | 4.24 | 3.14 | 3.57 | |
| Income quality | 0.88 | 1.55 | 1.02 | 1.33 | 1.74 | |
| Dividend Yield | 0.05 | 0.04 | 0.02 | 0.06 | 0.06 | |
| Payout ratio | 0.72 | 0.66 | 0.24 | 0.69 | 0.67 | |
| Sales general and administrative to revenue | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | |
| Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
| Intangibles to total assets | 0.02 | 0.04 | 0.03 | 0.03 | 0.03 | |
| Capex to operating cash flow | -1.49 | -0.43 | -0.42 | -0.4 | -0.31 | |
| Capex to revenue | -0.02 | -0.01 | -0.01 | -0.01 | -0.01 | |
| Capex to depreciation | -4.5 | -2.4 | -2.83 | -2.11 | -1.69 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 8.63 | 6.89 | 9.94 | 9.19 | 8.7 | |
| ROIC | 0.05 | 0.08 | 0.09 | 0.07 | 0.09 | |
| Return on tangible assets | 0.02 | 0.03 | 0.04 | 0.03 | 0.02 | |
| Graham Net | -1.44 | -1.57 | -1.48 | -1.32 | -1.78 | |
| Working capital | 12.79B | 12.95B | 14.82B | 15.78B | 15.97B | |
| Tangible asset value | 18.96B | 19.39B | 22.79B | 24.22B | 25.87B | |
| Net current asset value | 10.76B | 9.72B | 10.94B | 12.31B | 12.07B | |
| Invested capital | 0.64 | 0.78 | 0.81 | 0.73 | 0.62 | |
| Average receivables | 26.45B | 31.27B | 34.25B | 36.57B | 38.79B | |
| Average payables | 22.3B | 26.73B | 29.56B | 32.63B | 36.73B | |
| Average inventory | 13.04B | 13.98B | 14.42B | 15.15B | 16.36B | |
| Days sales outstanding | 126.86 | 118.31 | 119.36 | 109.98 | 105.79 | |
| Days payables outstanding | 116.64 | 112.64 | 112.48 | 110.76 | 110.77 | |
| Days of inventory on hand | 63.69 | 56.57 | 53.44 | 50.31 | 48.52 | |
| Receivables turnover | 2.88 | 3.09 | 3.06 | 3.32 | 3.45 | |
| Payables turnover | 3.13 | 3.24 | 3.25 | 3.3 | 3.29 | |
| Inventory turnover | 5.73 | 6.45 | 6.83 | 7.25 | 7.52 | |
| ROE | 0.07 | 0.09 | 0.14 | 0.1 | 0.08 | |
| Capex per share | -0.66 | -0.3 | -0.37 | -0.35 | -0.32 |
Quarterly Fundamentals Overview
Last date of statement is 2023-09-30 for Q3
| Metric | History | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 17.78 | 9.59 | 10.77 | 9.53 | 9.36 | |
| Net income per share | 0.24 | 0.09 | 0.14 | 0.2 | 0.13 | |
| Operating cash flow per share | 0.24 | 0.09 | 0.14 | 0.91 | 0.08 | |
| Free cash flow per share | 0.07 | 0.01 | 0.07 | 0.85 | 0.02 | |
| Cash per share | 7.71 | 4.48 | 3.89 | 4.1 | 3.86 | |
| Book value per share | 12.33 | 6.3 | 6.45 | 6.41 | 6.33 | |
| Tangible book value per share | 12.87 | 6.62 | 6.75 | 6.73 | 6.82 | |
| Share holders equity per share | 12.33 | 6.3 | 6.45 | 6.41 | 6.33 | |
| Interest debt per share | 8.71 | 3.97 | 4.48 | 4.33 | 4.47 | |
| Market cap | 10.78B | 24.43B | 27.99B | 28.96B | 28.94B | |
| Enterprise value | 12.69B | 22.46B | 30.06B | 29.64B | 30.98B | |
| P/E ratio | 5.74 | 17.64 | 12.47 | 9.26 | 15.05 | |
| Price to sales ratio | 0.31 | 0.65 | 0.66 | 0.78 | 0.83 | |
| POCF ratio | 22.95 | 70.56 | 49.87 | 8.18 | 103.04 | |
| PFCF ratio | 73.08 | 462.73 | 109.41 | 8.75 | 414.79 | |
| P/B Ratio | 0.44 | 0.99 | 1.11 | 1.16 | 1.22 | |
| PTB ratio | 0.44 | 0.99 | 1.11 | 1.16 | 1.22 | |
| EV to sales | 0.36 | 0.6 | 0.71 | 0.8 | 0.88 | |
| Enterprise value over EBITDA | 12.07 | 26.02 | 23.42 | 19.42 | 32.16 | |
| EV to operating cash flow | 27.03 | 64.85 | 53.57 | 8.37 | 110.31 | |
| EV to free cash flow | 86.07 | 425.33 | 117.53 | 8.95 | 444.03 | |
| Earnings yield | 0.04 | 0.01 | 0.02 | 0.03 | 0.02 | |
| Free cash flow yield | 0.01 | 0 | 0.01 | 0.11 | 0 | |
| Debt to equity | 0.69 | 0.62 | 0.68 | 0.66 | 0.69 | |
| Debt to assets | 0.18 | 0.16 | 0.18 | 0.18 | 0.18 | |
| Net debt to EBITDA | 1.82 | -2.29 | 1.62 | 0.44 | 2.12 | |
| Current ratio | 1.27 | 1.27 | 1.26 | 1.26 | 1.24 | |
| Interest coverage | 2.07 | 1.47 | 2.14 | 3.34 | 1.58 | |
| Income quality | 1 | 1 | 1 | 4.53 | 0.58 | |
| Dividend Yield | 0.03 | 0.01 | 0.01 | 0.04 | 0.01 | |
| Payout ratio | 0.59 | 0.43 | 0.33 | 1.35 | 0.55 | |
| Sales general and administrative to revenue | 0.04 | -0.03 | 0.02 | -0.01 | 0.05 | |
| Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
| Intangibles to total assets | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | |
| Capex to operating cash flow | -0.69 | -0.85 | -0.54 | -0.06 | -0.75 | |
| Capex to revenue | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 | |
| Capex to depreciation | -1.62 | -1.48 | -1.49 | -1.12 | 0.58 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 8.14 | 3.54 | 4.56 | 5.37 | 4.28 | |
| ROIC | 0.01 | 0.01 | 0.01 | 0.02 | 0.01 | |
| Return on tangible assets | 0.01 | 0 | 0.01 | 0.01 | 0.01 | |
| Graham Net | -3.53 | -1.78 | -2.05 | -1.93 | -2.18 | |
| Working capital | 16.45B | 15.97B | 16.59B | 16.05B | 14.91B | |
| Tangible asset value | 25.31B | 25.87B | 26.39B | 26.31B | 25.49B | |
| Net current asset value | 12.45B | 12.07B | 12.35B | 12.12B | 11.17B | |
| Invested capital | 0.69 | 0.62 | 0.68 | 0.66 | 0.69 | |
| Average receivables | 45.99B | 44.02B | 44.23B | 45.95B | 44.99B | |
| Average payables | 40.2B | 40.03B | 40.56B | 40.77B | 40.1B | |
| Average inventory | 14.54B | 15.81B | 16.79B | 16.59B | 16.06B | |
| Days sales outstanding | 121.85 | 97.74 | 102.12 | 106.57 | 117.9 | |
| Days payables outstanding | 113.35 | 102.34 | 96.74 | 105.84 | 112.44 | |
| Days of inventory on hand | 40.07 | 44.83 | 37.88 | 44.82 | 42.49 | |
| Receivables turnover | 0.74 | 0.92 | 0.88 | 0.84 | 0.76 | |
| Payables turnover | 0.79 | 0.88 | 0.93 | 0.85 | 0.8 | |
| Inventory turnover | 2.25 | 2.01 | 2.38 | 2.01 | 2.12 | |
| ROE | 0.02 | 0.01 | 0.02 | 0.03 | 0.02 | |
| Capex per share | -0.16 | -0.08 | -0.08 | -0.06 | -0.06 |
600998.SS Frequently Asked Questions
What is Jointown Pharmaceutical Group Co., Ltd stock symbol ?
Jointown Pharmaceutical Group Co., Ltd is a CN stock and trading under the symbol 600998.SS
What is Jointown Pharmaceutical Group Co., Ltd stock quote today ?
Jointown Pharmaceutical Group Co., Ltd stock price is $8.46 today.
Is Jointown Pharmaceutical Group Co., Ltd stock public?
Yes, Jointown Pharmaceutical Group Co., Ltd is a publicly traded company.
Company Profile
- Volume Average 17.21M
- Market Capitalization 31.47B
- Employee 30.14K
- CEO Mr. Wei He
- Headquarters Wuhan,CN
- IPO Date 2010-11-02
-
Website
https://www.jzteyao.com 
Jointown Pharmaceutical Group Co., Ltd provides marketing, distribution, and logistics services for digital pharmaceutical businesses. It wholesales Chinese herbal medicines, Chinese patent medicines, chemical medicinal materials, chemical medicine preparations, antibiotic preparations, biochemical drugs, biological products, chemical raw materials, and medical toxic drugs. The company was founded in 1999 and is based in Wuhan, China.
